Genmab (GMAB) and Pfizer (PFE) announced that the European Medicines Agency has validated for review the marketing authorization application of tisotumab vedotin, an antibody-drug conjugate, developed for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. If approved, tisotumab vedotin would be the first ADC granted European Union marketing authorization for people living with cervical cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Genmab price target raised to $50 from $49 at H.C. Wainwright
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
- Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
- Genmab downgraded to Sell from Neutral at Citi
